[exclusive] according to the data in the semi annual report, Fosun and China's pharmaceutical have achieved a revenue of 10 billion yuan, and the net profit of Kelun has increased rapidly. The R & D investment of tiger has exceeded the sales expense

Recently, the annual reports of various enterprises have been published one after another In the latest semi annual report, Fosun, Haizheng, Kelun, China Pharmaceutical and other famous enterprises have good semi annual performance Let's take a look at the latest simple performance data of several enterprises (including enterprises: China pharmaceutical, Fosun Pharmaceutical, Kelun pharmaceutical, China Resources Sanjiu, China Resources Shuanghe, Tongrentang, Bubu pharmaceutical, Haizheng pharmaceutical, Xinbang pharmaceutical, Kangyuan pharmaceutical and tiger pharmaceutical) revenue and net profit statement 1: half year revenue and net profit of the enterprise in 2018 half year: Fosun and China Pharmaceutical reach more than 10 billion In the first half of 2018, two large pharmaceutical enterprises, i.e China Pharmaceutical and Fosun Pharmaceutical, have more than 10 billion operating revenues among several enterprises that have published the latest interim annual report Although China's pharmaceutical industry has the highest revenue, its year-on-year growth is only 0.41% According to the annual report, the slowdown is mainly due to the "two vote system" and other related medical reform policies, which led to a sharp decrease in the business sector's business year-on-year; while Fosun Pharmaceutical achieved a 41.97% revenue growth this time, which is mainly due to the growth of core product sales and the contribution of new M & A enterprises According to the information, excluding the comparable factors of new M & A enterprises in 2017, the operating revenue increased by 23.44% compared with the same caliber in 2017 Next, there are 5 enterprises with a total value of less than 10 billion but more than 5 billion, which are Kelun, Tongrentang, China Resources 39, Bubu pharmaceutical and Haizheng pharmaceutical In addition, according to the year-on-year increase and decrease, it can be seen that the semi-annual income of Fosun, tiger and Cr Shuanghe has increased by more than 30%; however, the trend of step pharmaceutical is showing a small decline Figure 1 net profit of business income: Fosun reached 1.5 billion yuan, and Kelun increased rapidly, with a year-on-year increase of 202.17% Among the net profits of these enterprises, Fosun Pharmaceutical Co., Ltd is still in good shape Although there is a small decrease year on year, it is the highest among several enterprises, reaching 1.56 billion yuan According to the annual report of Fosun, the decrease is due to the decrease of the company's asset disposal income during the reporting period, resulting in a decrease of non recurring profit and loss of 61133200 yuan compared with the same period of last year, and a decrease of 67455700 yuan in recurring profit and loss In addition, the company with the largest increase in net profit was Kelun, with a year-on-year increase of 202.17% Figure 2 proportion of corporate net profit: Tiger's profit is good, and the sea is hovering steadily From the proportion of net profit and total operating income, tiger pharmaceutical has the highest proportion In the first half of 2018, the operating income and net profit income of tiger pharmaceutical have a significant increase, of which the main business income has a year-on-year growth of 38.99%, and the net profit has a year-on-year growth of 82.78% More than 10% of them are CR Shuanghe, Fosun, Cr Sanjiu, bu and Kangyuan It can be seen that the profits of these companies are relatively good It is worth noting that the profit situation of Haizheng in the half year is stable for the time being, and efforts need to be made in the second half of the year Figure 3 proportion of net profit in revenue R & D and sales table 2: R & D investment and sales expenses of half year 2018: Fosun reached about 1.2 billion, and Chinese medicine increased by 109.69% Among pharmaceutical enterprises, R & D investment is very important to maintain their sustainable competitiveness Among these enterprises, Fosun Pharmaceutical has the highest R & D investment, reaching 1.188 billion, an increase of 89.82% year on year According to the annual report, the increase is mainly due to the company's investment in R & D and consistency evaluation of monoclonal antibody bio innovative drugs, bio similar drugs and small molecule innovative drugs in the reporting period 。 In addition, it is worth noting that the R & D investment of Chinese medicine is less than 100 million, which is due to its industrial and commercial integration industrial pattern However, in the first half of 2018, the R & D investment started to increase significantly, which can be seen that its strategic pattern has changed in the new situation Figure 4 sales expenses of R & D investment of enterprises: Fosun, Buzhang is more than 3 billion yuan, with an increase of 219.53% in Chinese medicine In the first half of 2018, sales expenses of Fosun and Buzhang are more than 3 billion yuan Because of the scale of enterprises and products, there are big differences in sales expenses among enterprises It is worth mentioning that China's pharmaceutical sales expenses increased by 219.53% year-on-year According to the annual report, it is mainly because of the growth of the sales scale of the industrial sector, the impact of new medical policies and other factors that the company increased its investment attraction, sales service and publicity expenses Figure 5 proportion of R & D and sales in the sales expenses of enterprises: the famous cro company, tiger pharmaceutical, is on the same level, and the sales of most enterprises are much higher than that of R & D according to the ratio of R & D investment and sales investment to operating revenue, the R & D investment of tiger pharmaceutical is slightly higher than that of sales, which is related to the main business of the enterprise Tiger pharmaceutical is a famous cro enterprise in China While other enterprises have higher sales cost than R & D investment, which is the normal state of most domestic pharmaceutical enterprises The biggest difference is stepwise pharmaceutical, and the difference between R & D and sales accounts for 50 percentage points Figure 6 R & D and sales expenses Annex: drug related information of some enterprises in the first half of 2018 Fosun Pharmaceutical: During the reporting period, there were 240 projects for the research of new drugs, generic drugs, biological similar drugs and consistency evaluation, including 13 small molecule innovative drugs, 10 biological innovative drugs, 17 biological similar drugs, 131 international standard generic drugs, 55 consistency evaluation projects, 2 traditional Chinese medicines and 12 external introduction projects; in the first half of 2018, one drug clinical application was filed; 6 clinical approvals were obtained, including 3 for health One is chemical medicine and the other is chemical medicine Three drugs passed the consistency evaluation, namely, azadiazepine besylate tablets, escitalopram oxalate tablets, alfacalcitol tablets Kelun pharmaceutical: Nine generic drugs have been approved for production, three of which are the first generic drugs, namely amino acid glucose injection, fat emulsion (10%) / amino acid (15) / glucose (20%) injection, medium long chain fat emulsion / amino acid (16) / glucose (16%) electrolyte injection Six generic drugs have been applied for production, three of which are the first generic drugs, namely, tibiflodine tablets, dapoxetine hydrochloride tablets, vardenafil tablets Another drug was the first to pass the consistency evaluation, i.e escitalopram oxalate tablets Seven drugs were declared for consistency evaluation, three of which were the first to declare, respectively citalopram hydrobromide tablets, acyclovir tablets and Tinidazole tablets Chinese medicine: 68 research projects, 3 class 1 new drugs; 4 patent authorizations, 10 patent applications In addition, the approval documents of cefathiamidine for injection and clinical approval documents of tpn729ma project of class I new drug have been obtained; more than 30 drugs are being evaluated in terms of consistency evaluation, 7 of which are in be test, and 10 injection varieties are also being evaluated CR 39: 14 projects under research, 1.1 innovative traditional Chinese medicine In the first half of the year, it obtained 1 approval document for 6 kinds of supplementary application of traditional Chinese medicine and 3 new drug projects The consistency of azithromycin enteric coated capsules, erythromycin enteric coated capsules, azithromycin tablets and Mizolastine sustained-release tablets were evaluated During the reporting period, 7 national invention patents were applied for and 9 national invention patents were authorized China Resources Shuanghe: consistency evaluation of three drugs declaration, amlodipine besylate tablets passed the consistency evaluation Haizheng pharmaceutical: two oral solid preparations passed the consistency evaluation, namely, irbesartan tablets and rosuvastatin tablets The in vivo and in vitro evaluation of two varieties has been reported, and more than 10 varieties are in the process of in vivo and in vitro evaluation, and more than 10 injection varieties are in accordance with the requirements of injection consistency evaluation One biological drug obtained the supplementary application approval document, one obtained the clinical approval document, and several drugs were under research Kangyuan pharmaceutical: obtained 1 clinical approval document for new Chinese medicine and 5 national major scientific and technological projects The clinical reevaluation and basic research of evidence-based medicine were carried out around 13 main varieties of listed traditional Chinese medicine 22 authorized invention patents were obtained Tiger medicine: participated in 91 innovative drug varieties and more than 150 clinical research of innovative drugs 52 clinical trials of domestic innovative drugs are being carried out Information source: the semiannual report of each enterprise states that: the viewpoint of this article only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.